These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 33211534)

  • 21. Public preference for COVID-19 vaccines in China: A discrete choice experiment.
    Dong D; Xu RH; Wong EL; Hung CT; Feng D; Feng Z; Yeoh EK; Wong SY
    Health Expect; 2020 Dec; 23(6):1543-1578. PubMed ID: 33022806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Access to anti-covid vaccines: research, development and role of patents.].
    Formoso G; Mancini S
    Recenti Prog Med; 2021; 112(7):499-503. PubMed ID: 34263876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness and pricing of antibacterial drugs.
    Verhoef TI; Morris S
    Chem Biol Drug Des; 2015 Jan; 85(1):4-13. PubMed ID: 25521641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of pricing strategy on the costs of oral anti-cancer drugs.
    Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
    Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equitable distribution of COVID-19 vaccines.
    Burki T
    Lancet Infect Dis; 2021 Jan; 21(1):33-34. PubMed ID: 33357392
    [No Abstract]   [Full Text] [Related]  

  • 26. Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approach.
    Manheim D; Foster D
    F1000Res; 2020; 9():1154. PubMed ID: 33500777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Why a pioneering plan to distribute COVID vaccines equitably must succeed.
    Nature; 2021 Jan; 589(7841):170. PubMed ID: 33442047
    [No Abstract]   [Full Text] [Related]  

  • 28. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new approach to pharmaceutical pricing based on patients' willingness to pay.
    Rahimi F; Rasekh HR; Abbasian E; Peiravian F
    Trop Med Int Health; 2018 Dec; 23(12):1326-1331. PubMed ID: 30286256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead.
    Kaltenboeck A
    Value Health; 2020 Apr; 23(4):421-424. PubMed ID: 32327158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pricing the COVID-19 vaccine: A mathematical approach.
    Martonosi SE; Behzad B; Cummings K
    Omega; 2021 Sep; 103():102451. PubMed ID: 33785979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature.
    Arango-Luque A; Yucumá D; Castañeda CE; Espin J; Becerra-Posada F
    Value Health Reg Issues; 2024 Jul; 42():100981. PubMed ID: 38677063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice.
    Varghese MS; Liu CL; Kazi DS
    Curr Cardiol Rep; 2021 Oct; 23(11):163. PubMed ID: 34599393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A public health timeline to prepare for COVID-19 vaccines in Canada.
    MacDonald NE; Comeau J; Dubé E; Bucci L; Graham JE
    Can J Public Health; 2020 Dec; 111(6):945-952. PubMed ID: 33151510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of the U.S. response to COVID-19 in Global Health.
    Leineweber FV; Bermudez JAZ
    Cien Saude Colet; 2021 Mar; 26(3):1001-1012. PubMed ID: 33729354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EU's Ordering of COVID-19 Vaccine Doses: Political Decision-Making under Uncertainty.
    Gleißner W; Follert F; Daumann F; Leibbrand F
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33672157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analytics for vaccine economics and pricing: insights and observations.
    Robbins MJ; Jacobson SH
    Expert Rev Vaccines; 2015 Apr; 14(4):605-16. PubMed ID: 25435003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The lightning-fast quest for COVID vaccines - and what it means for other diseases.
    Ball P
    Nature; 2021 Jan; 589(7840):16-18. PubMed ID: 33340018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.